194 related articles for article (PubMed ID: 37508266)
1. Fluorescence Microscopy: Determination of Meropenem Activity against
Alieva KN; Golikova MV; Kuznetsova AA; Zinner SH
Antibiotics (Basel); 2023 Jul; 12(7):. PubMed ID: 37508266
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
Bulik CC; Christensen H; Li P; Sutherland CA; Nicolau DP; Kuti JL
Antimicrob Agents Chemother; 2010 Feb; 54(2):804-10. PubMed ID: 19995927
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of a New Variant OXA-204 and OXA-48 Carbapenemases Plasmids Encoded in Klebsiella pneumoniae Clinical Isolates in Tunisia.
Ouertani R; Ben Jomàa-Jemili M; Gharsa H; Limelette A; Guillard T; Brasme L; de Champs C; Chouchani C
Microb Drug Resist; 2018 Mar; 24(2):142-149. PubMed ID: 28737463
[TBL] [Abstract][Full Text] [Related]
4. Meropenem MICs at Standard and High Inocula and Mutant Prevention Concentration Inter-Relations: Comparative Study with Non-Carbapenemase-Producing and OXA-48-, KPC- and NDM-Producing
Golikova MV; Strukova EN; Alieva KN; Ageevets VA; Avdeeva AA; Sulian OS; Zinner SH
Antibiotics (Basel); 2023 May; 12(5):. PubMed ID: 37237775
[TBL] [Abstract][Full Text] [Related]
5. In vitro pharmacodynamics of various antibiotics in combination against extensively drug-resistant Klebsiella pneumoniae.
Lim TP; Cai Y; Hong Y; Chan EC; Suranthran S; Teo JQ; Lee WH; Tan TY; Hsu LY; Koh TH; Tan TT; Kwa AL
Antimicrob Agents Chemother; 2015 May; 59(5):2515-24. PubMed ID: 25691628
[TBL] [Abstract][Full Text] [Related]
6. Epidemiology and in vitro activity of ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam, eravacycline, plazomicin, and comparators against Greek carbapenemase-producing Klebsiella pneumoniae isolates.
Maraki S; Mavromanolaki VE; Magkafouraki E; Moraitis P; Stafylaki D; Kasimati A; Scoulica E
Infection; 2022 Apr; 50(2):467-474. PubMed ID: 34854060
[TBL] [Abstract][Full Text] [Related]
7. Impact of Ceftazidime-Avibactam Treatment in the Emergence of Novel KPC Variants in the ST307-Klebsiella pneumoniae High-Risk Clone and Consequences for Their Routine Detection.
Hernández-García M; Castillo-Polo JA; Cordero DG; Pérez-Viso B; García-Castillo M; Saez de la Fuente J; Morosini MI; Cantón R; Ruiz-Garbajosa P
J Clin Microbiol; 2022 Mar; 60(3):e0224521. PubMed ID: 35107303
[TBL] [Abstract][Full Text] [Related]
8. Carbapenem-Resistant
Ramadan RA; Bedawy AM; Negm EM; Hassan TH; Ibrahim DA; ElSheikh SM; Amer RM
Infect Drug Resist; 2022; 15():3537-3548. PubMed ID: 35833009
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study).
Kazmierczak KM; Tsuji M; Wise MG; Hackel M; Yamano Y; Echols R; Sahm DF
Int J Antimicrob Agents; 2019 Feb; 53(2):177-184. PubMed ID: 30395986
[TBL] [Abstract][Full Text] [Related]
10. Microbiological efficiency of the combinations of two carbapenems against antibiotic resistant Klebsiella pneumoniae strains.
Tapalski DV; Timoshkova EV; Petrovskaya TA; Osipkina OV; Karpov IA
Klin Lab Diagn; 2021 May; 66(5):304-309. PubMed ID: 34047517
[TBL] [Abstract][Full Text] [Related]
11. Comparison of disk diffusion, Etest and VITEK2 for detection of carbapenemase-producing Klebsiella pneumoniae with the EUCAST and CLSI breakpoint systems.
Vading M; Samuelsen Ø; Haldorsen B; Sundsfjord AS; Giske CG
Clin Microbiol Infect; 2011 May; 17(5):668-74. PubMed ID: 20649801
[TBL] [Abstract][Full Text] [Related]
12. Polymyxin B in combination with meropenem against carbapenemase-producing Klebsiella pneumoniae: pharmacodynamics and morphological changes.
Sharma R; Patel S; Abboud C; Diep J; Ly NS; Pogue JM; Kaye KS; Li J; Rao GG
Int J Antimicrob Agents; 2017 Feb; 49(2):224-232. PubMed ID: 28040408
[TBL] [Abstract][Full Text] [Related]
13. Meropenem-Vaborbactam Activity against U.S. Multidrug-Resistant
Shortridge D; Kantro V; Castanheira M
Microbiol Spectr; 2023 Feb; 11(1):e0450722. PubMed ID: 36622238
[TBL] [Abstract][Full Text] [Related]
14. [In Vitro Activity of Ceftazidime-avibactam and Colistin Against Carbapenem-Resistant Klebsiella pneumoniae Clinical Isolates].
Hoşbul T; Aydoğan CN; Kaya S; Bedir O; Gümral R; Albay A
Mikrobiyol Bul; 2022 Apr; 56(2):218-229. PubMed ID: 35477226
[TBL] [Abstract][Full Text] [Related]
15. Microbiology of Meropenem-Vaborbactam: A Novel Carbapenem Beta-Lactamase Inhibitor Combination for Carbapenem-Resistant Enterobacterales Infections.
Bhowmick T; Weinstein MP
Infect Dis Ther; 2020 Dec; 9(4):757-767. PubMed ID: 33017041
[TBL] [Abstract][Full Text] [Related]
16. [Comparison of phenotypic methods and polymerase chain reaction for the detection of carbapenemase production in clinical Klebsiella pneumoniae isolates].
Tekintaş Y; Çilli F; Eraç B; Yaşar M; Aydemir SŞ; Hoşgör Limoncu M
Mikrobiyol Bul; 2017 Jul; 51(3):269-276. PubMed ID: 28929963
[TBL] [Abstract][Full Text] [Related]
17. Is meropenem MIC increase against KPC-producing Klebsiella pneumoniae correlated with increased resistance rates against other antimicrobials with Gram-negative activity?
Cojutti P; Sartor A; Bassetti M; Scarparo C; Pea F
J Glob Antimicrob Resist; 2018 Sep; 14():238-241. PubMed ID: 29775786
[TBL] [Abstract][Full Text] [Related]
18. Comparison of meropenem MICs and susceptibilities for carbapenemase-producing Klebsiella pneumoniae isolates by various testing methods.
Bulik CC; Fauntleroy KA; Jenkins SG; Abuali M; LaBombardi VJ; Nicolau DP; Kuti JL
J Clin Microbiol; 2010 Jul; 48(7):2402-6. PubMed ID: 20484603
[TBL] [Abstract][Full Text] [Related]
19. In vitro evaluation of double carbapenem and colistin combinations against OXA-48, NDM carbapenemase-producing colistin-resistant Klebsiella pneumoniae strains.
Erdem F; Abulaila A; Aktas Z; Oncul O
Antimicrob Resist Infect Control; 2020 May; 9(1):70. PubMed ID: 32430058
[TBL] [Abstract][Full Text] [Related]
20. In vitro evaluation of dual carbapenem combinations against carbapenemase-producing Enterobacteriaceae.
Poirel L; Kieffer N; Nordmann P
J Antimicrob Chemother; 2016 Jan; 71(1):156-61. PubMed ID: 26416781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
